Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

Intellia Therapeutics Inc (NTLA)

  • Business News
  • Nov. 08, 2025, 22:13 UTC
  • 30
  • 1 comments

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Market reaction Comment Full text

Alnylam Pharmaceuticals Inc (ALNY)

  • Business News
  • Nov. 08, 2025, 21:57 UTC
  • 32
  • 1 comments

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

Market reaction Comment Full text

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Nov. 08, 2025, 20:43 UTC
  • 29
  • 1 comments

Best Computer Monitors For 2026

Market reaction Comment Full text

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Nov. 08, 2025, 20:41 UTC
  • 29
  • 1 comments

Best Indoor Home Security Cameras in 2026

Market reaction Comment Full text

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Nov. 08, 2025, 20:38 UTC
  • 29
  • 1 comments

Best Gaming Routers In 2026: Top Picks for Seamless Online Play

Market reaction Comment Full text

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Nov. 08, 2025, 20:35 UTC
  • 31
  • 1 comments

Best Business Printers For 2026: Top Models for Professional Office Use

Market reaction Comment Full text

9 Meters Biopharma, Inc. (NMTRQ)

  • Business News
  • Nov. 08, 2025, 20:31 UTC
  • 24
  • 1 comments

Best Android Watch For 2026

Market reaction Comment Full text

Merck & Company Inc (MRK)

  • Business News
  • Nov. 08, 2025, 19:30 UTC
  • 24
  • 1 comments

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Market reaction Comment Full text

Lexicon Pharmaceuticals Inc. (LXRX)

  • Business News
  • Nov. 08, 2025, 19:30 UTC
  • 21
  • 1 comments

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Market reaction Comment Full text

Vor Biopharma Inc (VOR)

  • Business News
  • Nov. 08, 2025, 16:45 UTC
  • 14
  • 1 comments

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Market reaction Comment Full text
  • Previous
  • 742
  • 743
  • 744
  • 745
  • 746
  • Next

Search

News categories

  • Technical Exchange News(10969)
  • Event(2441)
  • SEC News(193597)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(125910)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin